Case-Based Learning on Personalized Ovarian Response Optimization in Poor Responders

Abstract

Poor ovarian response (POR) to controlled ovarian stimulation remains a significant challenge in assisted reproductive technology (ART), notably affecting the prognosis of in vitro fertilization (IVF) cycles. Personalized ovarian response optimization, guided by patient-specific factors and emerging evidence, has gained traction as a strategy to maximize outcomes in this subset. This review integrates case-based learning to discuss epidemiology, pathophysiology, risk factors, clinical presentation, diagnosis, and evolving management paradigms in poor responders, highlighting the role of individualized protocols, advanced therapeutics, and guideline-based approaches for improved reproductive outcomes.

Introduction

Poor ovarian response is encountered in approximately 9–24% of women undergoing IVF, posing substantial clinical and emotional burdens. Traditional stimulation protocols often fail to yield an adequate number of oocytes, resulting in lower pregnancy rates and heightened cycle cancellation. The integration of case-based learning facilitates practical understanding of pathophysiological mechanisms and management strategies in poor responders, enabling clinicians to tailor interventions in line with the latest research and consensus recommendations. This article synthesizes evidence-based insights into the personalized optimization of ovarian stimulation in this challenging patient population.

Epidemiology / Disease Burden

Poor ovarian response is defined by a reduced number of retrieved oocytes (commonly <4) following standard stimulation protocols. Prevalence estimates vary depending on diagnostic criteria ranging from the Bologna criteria to the more recent POSEIDON classification. The burden is particularly pronounced in women of advanced reproductive age, impacting cumulative live birth rates. The psychological distress and increased resource utilization associated with repeated failed cycles underscore the importance of optimizing management in this group. Epidemiological data reveal that poor responders account for a disproportionate share of IVF failures, emphasizing the need for targeted interventions.

Pathophysiology

The pathophysiology of poor ovarian response is multifactorial, encompassing diminished ovarian reserve, intrinsic follicular dysfunction, altered gonadotropin receptor expression, and suboptimal intra-ovarian signaling. Genetic polymorphisms in FSH and LH receptors, mitochondrial dysfunction, and aberrant folliculogenesis are implicated in compromised ovarian responsiveness. Aging is a predominant factor, with declining follicular pool and oocyte quality. In some cases, iatrogenic causes such as prior ovarian surgery or chemotherapy contribute. Mechanistic insights have paved the way for personalized interventions targeting specific defects in the hypothalamic-pituitary-ovarian axis.

Risk Factors

Key risk factors for poor ovarian response include advanced maternal age, low anti-Müllerian hormone (AMH) levels, decreased antral follicle count (AFC), prior poor response to stimulation, genetic predisposition, and history of ovarian surgery or endometriosis. Lifestyle factors such as smoking, obesity, and exposure to environmental toxins may also play contributory roles. Identifying risk factors preemptively allows clinicians to counsel patients effectively and select appropriate stimulation protocols tailored to individual risk profiles.

Clinical Features

Poor responders typically present with a history of previous suboptimal response to ovarian stimulation, characterized by low oocyte yield and/or cycle cancellation. Clinical features may include oligomenorrhea, early follicular phase FSH elevation, and signs suggestive of diminished ovarian reserve. The emotional impact ranging from anxiety to frustration is significant, further complicating clinical management. Accurate identification relies on integrating clinical, biochemical, and ultrasonographic parameters within a robust diagnostic framework.

Diagnosis

Diagnosis of poor ovarian response is based on established criteria, most notably the Bologna and POSEIDON classifications. The Bologna criteria require at least two of the following: advanced maternal age (>40), history of poor response, and abnormal ovarian reserve tests (AMH <1.1 ng/mL or AFC <5–7). The POSEIDON group further stratifies patients by age, ovarian biomarkers, and previous response, allowing for more granular risk assessment. Diagnostic workup should include detailed reproductive history, hormonal profiling (AMH, FSH, estradiol), AFC, and exclusion of confounding factors such as thyroid dysfunction or hyperprolactinemia.

Treatment & Management

Management of poor responders necessitates individualized protocols based on patient characteristics and prior cycle outcomes. Conventional high-dose gonadotropin regimens have limited efficacy; thus, alternative approaches such as the use of mild stimulation, luteal phase stimulation, and dual stimulation protocols have been explored. Adjuvant therapies (e.g., androgens, growth hormone, coenzyme Q10) may improve follicular recruitment and oocyte quality in select patients. Cycle segmentation, natural cycle IVF, and oocyte accumulation over multiple cycles are additional strategies. Clinical decision-making should balance efficacy, patient burden, and cost-effectiveness while maintaining open communication regarding realistic expectations.

Recent Advances / Emerging Therapies

Recent advances encompass the adoption of personalized stimulation protocols, including the use of recombinant gonadotropins, LH supplementation, and individualized FSH dosing guided by pharmacogenomics and ovarian biomarker profiles. Emerging therapies such as in vitro activation (IVA) of dormant follicles, ovarian rejuvenation with platelet-rich plasma (PRP), and mitochondrial supplementation are under investigation. The POSEIDON criteria have facilitated more precise identification and stratification of poor responders, promoting research into targeted interventions. Ongoing trials are evaluating the role of microRNA modulation and stem cell therapy in restoring ovarian function, representing potential future breakthroughs.

Guideline Recommendations

International guidelines, including those from ESHRE and ASRM, underscore the importance of early identification and individualized management of poor responders. Recommendations emphasize the use of validated diagnostic criteria, patient counseling, consideration of adjuvant therapies on a case-by-case basis, and avoidance of overtreatment. Recent consensus supports the use of the POSEIDON stratification system to guide protocol selection and optimize outcomes. Multidisciplinary care, incorporating reproductive endocrinologists, embryologists, and mental health professionals, is advocated to address the complex needs of this patient cohort.

Conclusion

Poor ovarian response represents a substantial challenge in reproductive medicine, with significant implications for patient outcomes and resource utilization. Case-based learning, grounded in current evidence and guideline recommendations, highlights the necessity of personalized ovarian response optimization to maximize success rates in this difficult population. Advances in diagnostic stratification, individualized stimulation protocols, and emerging therapeutics hold promise for the future. Ongoing research and multidisciplinary collaboration will be pivotal in further refining management strategies and improving reproductive outcomes for poor responders.